Since TF is specifically expressed on angiogenic tumour VECs [1-5] and is also overexpressed by many types of cancer cells including solid cancers [1-6,12,25,37] and leukaemia [38-40], and since fVII-targeted VP PDT showed a stronger effect and better selectivity than free VP PDT for breast cancer in vitro and in vivo, we anticipate that this fVII-VP tPDT could have broad therapeutic potential for primary and metastatic tumours, not only for breast cancers but also for other tumours, as long as these tumours are laser light-accessible and express TF on their tumour cells and/or tumour VECs. This evidence concerns the gene TF and leukemia.